复发性胶质母细胞瘤二次手术后的结局:一项回顾性病例对照研究
该回顾性病例对照研究纳入澳大利亚两家三级医院2009年7月至2015年4月复发性胶质母细胞瘤患者120例(每家60例),按初次切除范围和年龄匹配二次手术与未手术患者。二次手术与化疗均与生存改善相关,术后功能结局令人鼓舞,作者指出需在手术技术改进和新型抗肿瘤治疗时代开展更多研究。
要点
- 二次手术与复发性胶质母细胞瘤生存改善相关(OS2:4.7 vs 9.6,HR 0.52,95%CI 0.38-0.72,P<0.001)。
- 复发时化疗亦改善生存(HR 0.47,95%CI 0.24-0.92,P=0.03)。
- 二次手术后80%无需康复治疗,61%可独立行走。
核心结论
- 复发性胶质母细胞瘤二次手术与生存获益相关,复发时化疗独立于手术亦改善生存,功能结局令人鼓舞。
- 作者指出需在手术技术改进和新型抗肿瘤治疗时代开展更多研究。
研究设计与样本
- 回顾性病例对照研究,纳入澳大利亚两家三级医院2009年7月至2015年4月复发性胶质母细胞瘤患者。
- 共120例(每家60例),诊断时中位年龄56岁,按初次切除范围和年龄匹配二次手术与未手术患者。
主要发现
- 未行二次手术者与二次手术者的中位OS1分别为14个月(95%CI 11.5-15.7)和22个月(95%CI 18-25)。
- 二次手术改善OS2(4.7 vs 9.6,HR 0.52,95%CI 0.38-0.72,P<0.001)。
- 复发时化疗改善生存(HR 0.47,95%CI 0.24-0.92,P=0.03)。
- 二次手术后80%无需康复治疗,61%可独立行走。
局限性
- 既往关于复发胶质母细胞瘤二次手术获益的研究因纳入不同级别胶质瘤、体能状态和切除范围的患者而存在混杂。
- 作者指出需在手术技术改进和新型抗肿瘤治疗时代开展更多研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Studies looking at the benefit of surgery at first relapse (second surgery) for recurrent glioblastoma were confounded by including patients with varying grades of glioma, performance status and extent of resection. This case-controlled study aims to remove these confounders to assess the survival impact of second surgery in recurrent glioblastoma. Retrospective data on patients with glioblastoma recurrence at two tertiary Australian hospitals from July 2009 to April 2015 was reviewed. Patients who had surgery at recurrence were matched with those who did not undergo surgery at recurrence, based on the extent of their initial resection and age. Overall survival (OS1 assessed from initial diagnosis and OS2 from the date of recurrence) as well as functional outcomes after resection were analysed. There were 120 patients (60 in each institution); median age at diagnosis was 56 years. Median OS1 was 14 months (95% CI 11.5-15.7) versus 22 months (95% CI 18-25) in patients who did not undergo second surgery and those with surgery at recurrence. OS2 was improved by second surgery (4.7 vs 9.6, HR 0.52, 95% CI 0.38-0.72, P < 0.001), and by chemotherapy, given at recurrence, (HR 0.47, 95% CI 0.24-0.92, P = 0.03). After second surgery, 80% did not require rehabilitation and 61% were independently mobile. Second surgery for recurrent glioblastoma was associated with a survival advantage. Chemotherapy independent of surgery, also improved survival. Functional outcomes were encouraging. More research is required in the era of improved surgical techniques and new antineoplastic therapies.
引用
- Wann A, Tully PA, Barnes EH, et al. Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study. J Neurooncol. 2018. PMID: 29294233. doi:10.1007/s11060-017-2731-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。